Seeking Alpha

Oxygen Biotherapeutics jumps on issuance of patent for its treatment of pruritus

  • Oxygen Biotherapeutics (OXBT +20%) pops after the USPTO issued the drug developer a patent earlier today for its treatment for pruritus - a sensation patients instinctually try to relieve by rubbing or scratching.
  • The company says it's currently evaluating commercialization strategies, which potentially includes out-licensing for conditions such as allergic contact dermatitis, psoriasis and acne.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)